Essentials• The Khorana score is validated for risk of venous thromboembolism (VTE) in
cancer outpatients.• We conducted a multicenter analysis of medically hospitalized cancer …

Inpatient venous thromboembolism (VTE) is a priority preventable illness; risk in cancer
varies and prophylaxis is inconsistently used. A previously validated tool (Khorana …

BACKGROUND: Venous thromboembolism is a well-known complication of malignancy.
The Khorana Risk Score (KRS) utilizes the type of cancer, blood counts, and body mass …

Background Guidelines do not recommend that cancer outpatients receive
thromboprophylaxis unless at high venous thromboembolism (VTE) risk, with the Khorana …

We aimed to evaluate the performance of the Khorana score in predicting venous
thromboembolic events in ambulatory cancer patients. Embase and MEDLINE were …

Background: Venous thromboembolism (VTE) prophylaxis remains underutilized,
particularly in cancer patients. We explored clinical predictors of prophylaxis in hospitalized …

Cancer and its treatment are recognized risk factors for VTE. Compliance rate with published
VTE prophylaxis guidelines is low. Decision on when to offer prophylaxis for hospitalized …

Introduction: Khorana score (KS) stratifies patients into low, intermediate, and high risk
groups for venous thromboembolism (VTE). We examined the generalizability of the KS to …

Background Oncology guidelines suggest using the Khorana score to select ambulatory
cancer patients receiving chemotherapy for primary venous thromboembolism (VTE) …

Venous thromboembolism (VTE) is a common complication of cancer and chemotherapy.
We evaluated the baseline clinical characteristics, thromboprophylaxis patterns, frequency …